{
  "docId": "019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "docSlug": "7d5a5b546ee496a809a6ede1a6c2c260",
  "documentTitle": "Equillium | Investor Presentation Deck | 32 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 32,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a side-by-side comparison structure to detail the status and upcoming milestones for two distinct clinical programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7b67-762e-8b55-8f35aa9a2cc0/7",
  "deckHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "deckJsonHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0.json",
  "deckAnchorHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.04,
        "y": 0.37
      },
      "kind": "list",
      "text": "EQUALISE Phase 1b in lupus nephritis: Fully enrolled, Open-label study, interim data demonstrated clinically meaningful response. Milestone: Topline data expected early 2024.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71a03a11-f293-4c84-a93c-18ae2753b8d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.52,
        "y": 0.37
      },
      "kind": "list",
      "text": "EQUATOR Pivotal Phase 3 in acute GVHD: Enrolling (n=200), Randomized controlled study (1:1), EQUATE Phase 1B study demonstrated high rates of rapid and durable complete response. Milestone: Interim Review @ 100 patients expected 2024.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4aa8cf6-b2ae-4e75-803c-db766441d0b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.925,
        "x": 0.038,
        "y": 0.215
      },
      "kind": "title",
      "text": "Itolizumab: Two Data Deliverables Expected in 2024",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a7c0f59-8ae2-44cc-9c56-577e561a8e87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.745,
        "x": 0.038,
        "y": 0.075
      },
      "kind": "title",
      "text": "Driving Development Towards Ono Option Decision",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f14f35cf-6764-4b2e-ab7f-45148b490b88",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 5,
      "beatId": "ad87164c-eefb-4286-988c-3da24e7ea3ff",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 5-23 present Equillium's platform and pipeline as a solution to the problems identified, providing relief for patients with immunological disorders.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}